Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A triple combination therapy trial assessing BXCL701, Avelumab and NKTR-214 in patients with pancreatic cancer

Next Previous
Trial Profile

A triple combination therapy trial assessing BXCL701, Avelumab and NKTR-214 in patients with pancreatic cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 12 Nov 2020 Status changed from planning to withdrawn prior to enrolment, according to a BioXcel Therapeutics media release.
  • 12 Nov 2020 According to a BioXcel Therapeutics media release, the company along with Nektar and Pfizers, have agreed to discontinue activities on the triple combination study and instead reallocate resources to other studies and development programs.
  • 13 Mar 2020 According to a BioXcel Therapeutics media release, this trial is expected to be initiated following Nektar and Pfizers safety run-in trial of a double combination of bempegaldesleukin and avelumab and the outcome of that trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top